Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
3.330
-0.230 (-6.46%)
At close: Apr 6, 2026, 4:00 PM EDT
3.430
+0.100 (3.00%)
Pre-market: Apr 7, 2026, 7:35 AM EDT
Plus Therapeutics Employees
Plus Therapeutics had 28 employees as of December 31, 2025. The number of employees increased by 7 or 33.33% compared to the previous year.
Employees
28
Change (1Y)
7
Growth (1Y)
33.33%
Revenue / Employee
$186,179
Profits / Employee
-$799,500
Market Cap
22.85M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 28 | 7 | 33.33% |
| Dec 31, 2024 | 21 | 1 | 5.00% |
| Dec 31, 2023 | 20 | 3 | 17.65% |
| Dec 31, 2022 | 17 | 3 | 21.43% |
| Dec 31, 2021 | 14 | 2 | 16.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 59 |
| Curis | 24 |
| Tempest Therapeutics | 21 |
| Quantum BioPharma | 17 |
| Outlook Therapeutics | 17 |
| Barinthus Biotherapeutics | 14 |
| Skye Bioscience | 12 |
| Neuphoria Therapeutics | 8 |
PSTV News
- 5 days ago - Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives - GlobeNewsWire
- 6 days ago - Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors - GlobeNewsWire
- 19 days ago - Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40% - GlobeNewsWire
- 25 days ago - Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™ - GlobeNewsWire
- 2 months ago - Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET - GlobeNewsWire
- 2 months ago - Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges - Benzinga